IN2014MN01714A - - Google Patents
Info
- Publication number
- IN2014MN01714A IN2014MN01714A IN1714MUN2014A IN2014MN01714A IN 2014MN01714 A IN2014MN01714 A IN 2014MN01714A IN 1714MUN2014 A IN1714MUN2014 A IN 1714MUN2014A IN 2014MN01714 A IN2014MN01714 A IN 2014MN01714A
- Authority
- IN
- India
- Prior art keywords
- methods
- dried formulations
- drying
- polyol
- dried
- Prior art date
Links
- 238000009472 formulation Methods 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 2
- 229910052751 metal Chemical class 0.000 abstract 2
- 239000002184 metal Chemical class 0.000 abstract 2
- 229920005862 polyol Polymers 0.000 abstract 2
- 150000003077 polyols Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 241000991587 Enterovirus C Species 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 159000000003 magnesium salts Chemical group 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 238000001291 vacuum drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606577P | 2012-03-05 | 2012-03-05 | |
| EP12158086 | 2012-03-05 | ||
| PCT/NL2013/050139 WO2013133702A1 (en) | 2012-03-05 | 2013-03-05 | Methods and compositions for stabilizing dried biological materials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01714A true IN2014MN01714A (enExample) | 2015-05-29 |
Family
ID=49117091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1714MUN2014 IN2014MN01714A (enExample) | 2012-03-05 | 2013-03-05 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9827303B2 (enExample) |
| EP (1) | EP2822540B1 (enExample) |
| JP (1) | JP6253161B2 (enExample) |
| KR (1) | KR102108876B1 (enExample) |
| CN (1) | CN104271119B (enExample) |
| AU (1) | AU2013228096B2 (enExample) |
| BR (1) | BR112014020930A2 (enExample) |
| CA (1) | CA2865551C (enExample) |
| IN (1) | IN2014MN01714A (enExample) |
| WO (1) | WO2013133702A1 (enExample) |
| ZA (1) | ZA201407198B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274827B (zh) * | 2013-07-01 | 2020-07-14 | 上海贺普药业股份有限公司 | 贺普拉肽的制剂 |
| WO2015097650A1 (en) | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| CA3027454A1 (en) * | 2016-06-16 | 2017-12-21 | Janssen Vaccines & Prevention B.V. | Hiv vaccine formulation |
| US11116955B2 (en) | 2017-02-24 | 2021-09-14 | Hisamitsu Pharmaceutical Co., Inc. | Method for producing microneedle device |
| US20200085941A1 (en) * | 2017-04-28 | 2020-03-19 | Universal Stabilization Technologies, Inc. | Antigenic thermostable polio vaccines & related methods |
| CA3069444A1 (en) * | 2017-07-11 | 2019-01-17 | Universal Stabilization Technologies, Inc. | Method for preserving biopharmaceuticals |
| CN111166891B (zh) * | 2018-11-13 | 2022-04-05 | 中国药科大学 | 甘露醇共晶辅料及其制备方法和用途 |
| CN112111609A (zh) * | 2020-10-29 | 2020-12-22 | 上海伯杰医疗科技有限公司 | 一种肠道病毒通用型核酸检测试剂盒 |
| CN114748615A (zh) * | 2022-04-29 | 2022-07-15 | 成都安永鼎业生物技术有限公司 | 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途 |
| CN115089864B (zh) * | 2022-07-14 | 2023-12-29 | 复旦大学 | 一种使用冷冻干燥技术制备可溶性微针贴片的方法 |
| CN116763914B (zh) * | 2023-02-06 | 2024-02-23 | 广东永顺生物制药股份有限公司 | 猪瘟、高致病性猪繁殖与呼吸综合征二联耐热保护剂活疫苗及其制备方法 |
| CN117482072A (zh) * | 2023-11-17 | 2024-02-02 | 上海市浦东新区公利医院(第二军医大学附属公利医院) | 山梨糖醇在制备治疗呼吸道合胞病毒所致疾病的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| JPH0761955B2 (ja) * | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | 凍結乾燥ａ型肝炎ワクチン |
| PT939648E (pt) * | 1996-09-26 | 2008-01-11 | Merck & Co Inc | Formulações de vacinas de rotavírus |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| EP2420247A1 (en) * | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| WO2001093829A2 (en) * | 2000-06-08 | 2001-12-13 | Powderject Vaccines, Inc. | Powder compositions |
| GB0020089D0 (en) | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
| FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| AU2004299057B2 (en) * | 2003-12-17 | 2010-06-24 | Wyeth Llc | Methods for porducing storage stable viruses and immunogenic compositions thereof |
| LT1699919T (lt) | 2003-12-24 | 2017-04-25 | De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport | Respiracinis sincitinis virusas su genomo deficitu, komplementuotas in trans |
| GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| TWI398272B (zh) | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| EP1909831A4 (en) * | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| BR112012016021A8 (pt) | 2009-12-11 | 2018-06-12 | Bind Biosciences Inc | Formulações estáveis para liofilização de partículas terapêuticas |
-
2013
- 2013-03-05 IN IN1714MUN2014 patent/IN2014MN01714A/en unknown
- 2013-03-05 EP EP13709589.9A patent/EP2822540B1/en active Active
- 2013-03-05 AU AU2013228096A patent/AU2013228096B2/en not_active Ceased
- 2013-03-05 JP JP2014560879A patent/JP6253161B2/ja not_active Expired - Fee Related
- 2013-03-05 US US14/382,258 patent/US9827303B2/en active Active
- 2013-03-05 WO PCT/NL2013/050139 patent/WO2013133702A1/en not_active Ceased
- 2013-03-05 CA CA2865551A patent/CA2865551C/en active Active
- 2013-03-05 KR KR1020147024688A patent/KR102108876B1/ko not_active Expired - Fee Related
- 2013-03-05 CN CN201380023800.9A patent/CN104271119B/zh not_active Expired - Fee Related
- 2013-03-05 BR BR112014020930A patent/BR112014020930A2/pt active Search and Examination
-
2014
- 2014-10-03 ZA ZA2014/07198A patent/ZA201407198B/en unknown
-
2017
- 2017-10-27 US US15/795,545 patent/US10335479B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013133702A1 (en) | 2013-09-12 |
| AU2013228096B2 (en) | 2017-07-13 |
| KR20150008848A (ko) | 2015-01-23 |
| JP2015509529A (ja) | 2015-03-30 |
| US10335479B2 (en) | 2019-07-02 |
| AU2013228096A1 (en) | 2014-09-11 |
| ZA201407198B (en) | 2016-02-24 |
| CA2865551A1 (en) | 2013-09-12 |
| EP2822540A1 (en) | 2015-01-14 |
| CN104271119B (zh) | 2018-07-10 |
| CA2865551C (en) | 2021-01-12 |
| BR112014020930A2 (pt) | 2017-06-27 |
| US20180055924A1 (en) | 2018-03-01 |
| KR102108876B1 (ko) | 2020-05-12 |
| US9827303B2 (en) | 2017-11-28 |
| JP6253161B2 (ja) | 2017-12-27 |
| US20150030629A1 (en) | 2015-01-29 |
| CN104271119A (zh) | 2015-01-07 |
| EP2822540B1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01714A (enExample) | ||
| PH12018500856A1 (en) | Respiratory syncytial virus vaccine | |
| WO2017070626A3 (en) | Respiratory virus vaccines | |
| BR112016006326A2 (pt) | formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina | |
| CY1122292T1 (el) | Ενωσεις και μεθοδοι για αντιϊικη αγωγη | |
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| WO2017070620A3 (en) | Broad spectrum influenza virus vaccine | |
| CL2014000762A1 (es) | Uso de particulas de un ingrediente alimenticio absorbente de agua insoluble como un portador para el agua y/o un humectante, porque sirve para la introduccion de agua en un producto de chocolate; agente de tropicalizacion; producto de chocolate tropicalizado; metodo para la preparacion de dicho agente; y metodo para mejorar la estabilidad al calor | |
| PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
| EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| MX383706B (es) | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. | |
| IL241164B (en) | History of phenyl-acetic acid and 3-phenyl-propionic acid for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| UA113956C2 (xx) | Похідні піримідину для лікування вірусних інфекцій | |
| PH12015502230B1 (en) | Novel viral replication inhibitors | |
| MX373096B (es) | Formulaciones virales líquidas. | |
| MX349294B (es) | Formulaciones virales liofilizadas. | |
| MX361408B (es) | Un herpesvirus koi recombinante y vacuna para la prevención de una enfermedad causada por herpesvirus koi. | |
| WO2014116772A3 (en) | Squaric derivatives for the treatment of hepatitis c | |
| PH12015502717B1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| DK2870141T3 (da) | Methanthion-forbindelser med antivirus-aktivitet | |
| WO2014137249A3 (ru) | Способ изготовления вакцины против ящура | |
| BR112014018411A8 (pt) | Composto de fórmula (i), composto de fórmula (ii), formulação farmacêutica, método para a preparação de um composto de fórmula (ii) e cepa de microrganismo | |
| Balić et al. | Working team for trichinellosis-a systematic approach to prevention, control and eradication of trichinellosis in the Republic of Croatia | |
| EA201990314A1 (ru) | Новые ингибиторы вирусной репликации |